Extended Data Fig. 4: HPFs acquire CAF properties after MitoCeption with cancer cell mitochondria.
a. qRT-PCR for INHBA, IL6, COL1A1 and ACTA2 relative to RPL13A using RNA from MitoCepted (A431 mitochondria) or mock-treated HPFs. n = 3 cultures per group. b. qRT-PCR for ISG15, ISG20, and OASL relative to RPL27 using RNA from MitoCepted or mock-treated HPFs. n = 3 cultures per group. c. BCA protein quantification in mitochondrial lysates from 107 HaCaT or A431 cells. n = 3 cultures per cell line. d. Seahorse analysis of HPFs subjected to MitoCeption with A431 or HaCaT mitochondria or mock treatment, and of A431 cells. n = 5 cultures per group. e. Basal respiration and proton leak of HPFs, subjected to MitoCeption with HaCaT or HaCaT-Ras mitochondria or mock treatment, determined by Seahorse XF stress test. n = 5 cultures per group. f. qRT-PCR for INHBA, IL6, COL1A1 and ACTA2 relative to RPL27 using RNA from HPFs subjected to MitoCeption with MitoTracker Green-stained mitochondria from A431 cancer cells, pre-treated with oligomycin or mock treatment. n = 3 cultures per group. g. Percentage of Ki67-positive HPFs subjected to MitoCeption with MitoTracker Green-stained mitochondria from A431 cancer cells, pre-treated with oligomycin or mock treatment. n = 3 cultures per treatment group. Graphs show mean ± SEM. Unpaired two-sided Student’s t-test (a–c) or two-sided one-way ANOVA with Bonferroni post-host multiple comparison test (e–g) were used to determine statistical significance.